生物试剂
>
生化试剂
>
信号通路
> 醋酸阿肽地尔
加入收藏 取消收藏

醋酸阿肽地尔  ≥98%

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

件 库存{{model.attbuying.number}}件
立即购买 加入购物车 下载说明书

看了又看
包装规格：1mg 5mg 10mg 25mg 50mg 100mg in glass bottle
产品简介：是一种模拟血管活性肠多肽 (VIP) 类似物，具有强的血管舒张 (vasodilatory) 效应。。Aviptadil acetate 诱导肺血管扩张，抑制血管 SMCs 增殖、血小板聚集。Aviptadil acetate 可用于肺纤维化、肺动脉高压 (PAH)、SARS-CoV-2 引起呼吸衰竭等的研究。
溶解性：溶于DMSO（100 mg/mL 超声）
储备液保存：-80°C, 6 months -20°C, 1 month (sealed storage, away from moisture and light)
体内实验：1、请依序添加每种溶剂： 10% DMSO→40% PEG300→5% Tween-80→45% Saline Solubility: ≥ 2.5 mg/mL (0.74 mM); 澄清溶液 此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水 定容至 1 mL。 2、请依序添加每种溶剂： 10% DMSO→90% (20% SBE-β-CD in Saline) Solubility: 2.5 mg/mL (0.74 mM); 悬浊液; 超声助溶 此方案可获得 2.5 mg/mL的均匀悬浊液，悬浊液可用于口服和腹腔注射。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中，混合均匀。 3、请依序添加每种溶剂： 10% DMSO→90% Corn Oil Solubility: ≥ 2.5 mg/mL (0.74 mM); 澄清溶液 此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。 4、请依序添加每种溶剂： PBS Solubility: 50 mg/mL (14.77 mM); 澄清溶液; 超声助溶 ＜1mg/ml表示微溶或不溶。 普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
靶点：SARS-CoV
体外研究：Aviptadil acetate inhibits the basal proliferation of pulmonary arterial smooth muscle cells (PASMC) and the mobilization of intracellular free calcium concentration in these cells in a dose-dependent manner. Aviptadil acetate (1 nM-10μM) produces a concentration-dependent inhibition of CSE-induced cell death in L2 cells. At 10μM, Aviptadil acetate reduces CSE-stimulated MMP activity and caspase-3 activation in L2 cells. Aviptadil acetate (10 nM-100μM) attenuates lipopolisaccharide (LPS)-induced MMP-9 activity and its expression by alveolar macrophages (AM) in rats.
体内研究：Aviptadil acetate (1, 3 and 10mg/kg; intravenous bolus injection) is injected into a tail vein. No-effect dose level is 1mg/kg.Dose level with first intolerance reactions 3 mg/kg, Lowest lethal dose level is >10mg/kg. i.v. LD50 of Aviptadil is >10 mg/kg in males, females and male and female combined after 24hours and 14 days. Aviptadil acetate (intravenous bolus injection) at 3 mg causes slightly reduced motility, slight ataxia and slight dyspnoea in all 5 male and 5 female animals 15 to 30minutes after administration. At 10mg, Aviptadil reveals slightly reduced motility,slight ataxia, and slight dyspnoea 15 to 60 minutes and slightly reduces muscle tone 15 to 30minutes after administration,respectively, in all male and female animals.Nose-only inhalation exposure of CD1 mice to aerosolized. Aviptadil acetate at a dose of 1546µg/kg/day is well tolerated and produces no apparent changes in any of the parameters evaluated. No changes are observed after a single dose administration as high as 3920µg/kg/day. The no observableadverse-effect level (NOAEL) is considered to be at least 3920µg/kg/day fore an acute exposure and 1546 µg/kg/day for a 10 day repeated exposure.
保存条件：-20℃
注意事项：1、为了您的安全和健康，请穿实验服并戴一次性手套操作。 2、以上信息仅做参考交流之用。

猜你喜欢